Therapeutics Phase 1 Study ABT751 Combination With CAPIRI Capecitabine Irinotecan Bevacizumab Patients With Advanced Colorectal Cancer The Journal Clinical Pharmacology 2016 568 966973 Ccid2 2016 The Authors The Journal Clinical Pharmacology Published Wiley Periodicals Inc behalf American College Clinical Pharma cology DOI 101002jcph681 Michelle A Rudek PharmD PhD1 Arvind Dasari MD2 Daniel Laheru MD1 Ping He BS1 Runyan Jin PhD1 Rosalind Walker BS1 Gretchen E Taylor BS1 Antonio Jimeno MD PhD12 Ross C Donehower MD1 Manuel Hidalgo MD PhD13 Wells A Messersmith MD12 W Thomas Purcell MD MBA12 Abstract ABT751 orally bioavailable sulfonamide antimitotic properties A nonrandomized phase 1 doseescalation study ABT751 combination CAPIRI capecitabine irinotecan bevacizumab conducted define maximum tolerated dose doselimiting toxicity DLT pharmacokinetics patients advanced colorectal cancer Patients treated ABT751 daily 7 days began 21day cycles treatment ABT751 daily capecitabine twice daily 14 days plus irinotecan day 1 intravenously Bevacizumab added standard care 75 mgkg day 1 2 dose levels Because intolerance regimen reduced dose ABT751 explored reduceddose fulldose CAPIRI bevacizumab ABT751 irinotecan pharmacokinetics ABT751 glucuronidation protein binding explored Twentyfour patients treated 5 dose levels The maximum tolerated dose ABT751 125 mg combined fulldose CAPIRI bevacizumab 75 mgkg day 1 DLTs hypokalemia elevated liver tests febrile neutropenia ABT751 metabolized UGT1A8 lesser extent UGT1A4 UGT1A1 Irinotecan APC exposure increased SN38 exposure similar SN38 glucuronide exposure decreased Clinically relevant alterations ABT751 irinotecan pharmacokinetics observed Despite modest efficacy combination ABT751 CAPIRI bevacizumab studied colorectal cancer Keywords colorectal cancer tubulin inhibitor toxicity pharmacokinetics Colorectal cancer leading cause cancerrelated deaths estimated incidence 140000 cases caused estimated 51000 deaths 2010 In spite extensive research patients advanced colorectal cancer continue disappointingly poor outcomes 5year survival rates 5 61 intracellular Microtubules play vital role cell functions including cell movement transport cell division Disruption microtubules arrests leading cell cycle G2M checkpoint apoptosis2 ABT751 N24hydroxyphenylamino Abbott 3pyridinyl4methoxybenzenesulfonamide Laboratories Abbott Park orally bioavailable sulfonamide molecule binds colchicine binding site βtubulin inhibits microtubule polymerization functioning3 In addition ABT751 appears vascular disrupting agent reducing blood flow tumors enhancing cytotoxic effects little effect normal vasculature suggesting possible synergistic activity vascular endothelial growth factor VEGF directed therapies bevacizumab4 Preclinical Illinois evidence suggests significant activity tumor types including colon cancer vitro cell lines5 vivo xenografts syngeneic models69 Furthermore mouse xenograft experiments suggest ABT751 additive effects 5FU colon cancer10 Early phase 1 clinical trials suggest ABT751 favorable pharmacokinetic profile 1Sidney Kimmel Comprehensive Cancer Center Johns Hopkins University Baltimore MD USA 2University Colorado Cancer Center Denver CO USA 3Centro Integral Oncologico Clara Campal Madrid Spain This open access article terms Creative Commons AttributionNonCommercialNoDerivs License permits use distribution medium provided original work properly cited use noncommercial modifications adaptations Submitted publication 20 January 2015 accepted 11 November 2015 Corresponding Author W Thomas Purcell MD University Colorado Cancer Center Anschutz Cancer Pavilion Aurora CO 80045 Email tompurcellucdenveredu These authors contributed equally work presented Rudek et al rapid absorption maximum concentration Cmax reached 3 hours administration half life ranging 44 166 hours concentrations associated preclinical efficacy11 With prolonged administration schedules 7 21day schedules twicedaily dosing common toxicities peripheral neuropathy ileus fatigue Notably significant myelosupression observed favoring combination myelosuppressive regimens91214 Irinotecan combination infusional 5FU FOLFIRI bevacizumab mono clonal antibody human VEGF standard regimen metastatic colon cancer At time initiation trial capecitabine consid ered possible replacement infusional 5FU FOLFIRI CAPIRI based phase 12 trials role bevacizumab combination drug regimens capecitabine ex plored Finally role continuing bevacizumab patients progressed firstline therapy unclear Given promising preclinical data nonoverlapping toxicities possible synergistic ac tivity current clinical trial treated metastatic colorectal cancer patients combination CAPIRI bevacizumab ABT751 Patients Methods Approval institutions institutional review board obtained written informed consent mandatory prior enrollment Patient Eligibility Patients advanced unresectable histologically confirmed metastatic locally advanced colorectal adenocarcinoma eligible untreated treated 1 prior nonirinotecan containing regimen advanced disease cid218 years age measurable disease Karnofsky performance score cid260 life expectancy cid212 weeks absolute granulocyte count 1500μL platelet count 100000μL serum bilirubin level cid32 mgdL normal renal function transaminases 25 upper limit normal ULN ULN 5 ULN case liver metastases Patients chemotherapy andor radiotherapy 3 weeks prior enrollment Patients excluded brain metastases peripheral neuropathy grade 1 severe comorbid health conditions lacked ability comply Drug Dosage Administration ABT751 administered orally daily monotherapy day 14 day 8 lead Table 1 Patient Characteristics n 24 Characteristic Gender Male Female Age years Median Range ECOG performance status 0 1 Cancer diagnosis Colon Rectal Colorectal Prior treatmenta None 1 Chemotherapy regimen 2 Chemotherapy regimens Radiotherapy Hormonal therapy n 17 7 575 3482 15 9 15 3 6 2 13 5 5 1 967 71 29 63 37 63 12 25 4 54 21 21 4 ECOG Eastern Cooperative Oncology Group aIncluding adjuvant therapy period combination capecitabine irinotecan CAPIRI bevacizumab days 1 14 21day cycle stan dard antiemetics 5HT3 antagonist dexametha sone CAPIRI consists capecitabine administered orally 2 divided doses days 1 14 irinotecan administered intravenously 2 hours day 1 The dose levels ABT751 CAPIRI presented Table 1 During course study bevacizumab standard care incorporated regimen1516 Bevacizumab 75 mgkg administered intravenously 90 minutes day 1 added regimen day 1 dose level 2b In absence treatment delays result adverse events treat ment continued disease progression intercurrent illness unacceptable adverse events withdrawal consent Assessments FollowUp Monitoring Before study entry patients clinical history physical examination performance status toxicity assessment CBC chemistries PTaPTT urinalysis pregnancy test applicable chest xray ECG disease assessment CEA computed tomography CT andor magnetic resonance imaging MRI A history physical examination performance status toxicity assessments CBC chemistry panel performed day 14 day 1 cycle CT scans disease sites performed baseline 2 3 weeks study entry 2 cycles sooner clinically indicated Additional 968 The Journal Clinical Pharmacology Vol 56 No 8 2016 assessments adverse effects day 8 weekly cycle 1 day 15 subsequent cycles Adverse events classified graded according National Cancer Institute Common Terminology Criteria Adverse Events version 3 Response evaluated Response Evaluation Criteria Solid Tumors 1017 Definition DoseLimiting Toxicity MTD Dose Escalation Plan Doselimiting toxicity DLT determined toxi cities seen prior end cycle defined drugrelated grade 4 neutropenia cid25 days grade 3 4 neutropenia fever grade 4 thrombocytopenia grade 3 4 nonhema tological toxicity excluding nauseavomiting diarrhea constipation appropriate preventive regi men use grade 2 symptomatic toxicity persisting longer 7 days despite appropriate supportive treatment delay treatment cid23 weeks toxicity Each dose level cohort consisted 3 patients nonevaluable subjects received 85 cycle 1 dosing replaced If 33 patients developed DLT dose escalated level The maximum tolerated dose MTD defined dose level cid233 patients develop similarly grouped DLT A total 6 12 patients treated MTD better toxicity pharmacology characterization Pharmacokinetic Sampling Analytic Assay ABT751 Pharmacokinetic studies performed leadin phase cycle 1 ABT751 Se rial sampling venous blood performed day 14 prior treatment steady state lead phase day 9 combination CAPIRI day 8 prior treatment 05 1 2 3 4 5 6 8 24 hours posttreatment Blood samples collected tubes containing EDTA processed centrifugation 10 minutes 1000g 4C Plasma frozen 70C analysis Total plasma concentrations ABT751 sulfate glucuronide metabolites determined high performance liquid chromatography mass spec trometric detection LCMSMS18 Calibration curves generated range 20 5000 ngmL ABT751 metabolites 110 dilution allowing quantitation 50000 ngmL Quality assurance samples assayed analytic run 15 nominal concentration Unbound plasma concentrations ABT751 determined equilibrium dialysis method 96well microdialysis plates optimized validated determining fraction unbound f u human plasma19 The degree ABT751 pro tein binding assessed isolated protein solu tions containing human serum albumin HSA human α1acid glycoprotein AAG described Sampling Analytic Assay Pharmacokinetic Irinotecan Pharmacokinetic studies performed cycle 1 day 1 irinotecan Blood samples collected following times prior treatment 05 hour irinotecan infusion 5 minutes end infusion postinfusion 017 05 1 2 4 75 24 48 hours end infusion Blood samples collected heparinized tubes processed centrifugation 10 minutes 1000g 4C Plasma frozen 70C time analysis Total plasma concentrations total lactone carboxylate irinotecan metabolites SN38 SN38 glucuronide SN 38G APC determined reversephase high performance liquid chromatography fluorescence detection modification procedure described previously2021 Irinotecan SN38 SN38G APC quantitated range 10 3000 2 600 100 600 2 600 ngmL respectively SN38G measured indirectly quantitation peak area retention time SN38G SN38 calibration curve previously described2021 A limited SN38G available confirm reten tion time metabolite Aventis Pharma Vitro surSeine Cedex France Quality assurance samples assayed analytic run 15 nominal concentration Pharmacokinetic Data Analysis Individual plasma concentrations total bound ABT751 ABT751 sulfate ABT751 glu curonide irinotecan SN38 SN38G APC analyzed noncompartmental methods imple mented software program WinNonlin version 53 Pharsight Inc Mountain View Califor nia Reported pharmacokinetic parameters included maximum plasma concentration Cmax time Cmax Tmax area plasma concentration time curve AUC value dosing interval steadystate AUCτ ABT751 extrapolated infinity AUCcid4 irinotecan AUC ratios demonstrate relative extent metabolism ABT751 irinotecan If correlation coefficient r λz 09 AUC extrapolated infinity AUCcid4 equation AUCcid4 AUClast Clast λz Clast final quan tifiable concentration Additionally percentage extrapolated greater 20 AUCcid4 Rudek et al 969 reported The observed exposure parameters Cmax AUCcid4 irinotecan metabolites dose normalized 250 mgm2 applying cor rection normalized parameter observed parameter 250actual dose22 Drug Metabolism In vitro metabolism studies conducted ing recombinant UDP glucuronosyltransferase UGT isozymes standard techniques23 The initial screen activity performed 05mL reac tion incubated 37C 60 minutes containing 1 mgmL protein 2 mM uridine diphosphoglucuronic acid UDPGA 8 mM magnesium chloride 25 μgmL alamethicin 025 methanol 9 μM ABT751 50 mM Tris pH 75 All reactions determine Km Vmax UGT1A1 UGT1A4 UGT1A8 conducted 37C conditions produced glucuronidation products linear respect time protein concentration ABT751 ABT 751 glucuronide quantitated extracts vitro drug metabolism studies LCMSMS18 Mi crosomal kinetic data fit MichaelisMenten model Apparent Km Vmax intrinsic clearance VmaxKm calculated accordingly Statistical Analysis Descriptive statistics summarize pa tient characteristics efficacy safety data Pharma cokinetic parameters summarized descriptive statistics dosenormalized parameters dose dependent parameters actual values dose independent parameters A KruskalWallis analysis variance ranks compare ABT 751 pharmacokinetic parameters dose levels A Wilcoxon matchedpairs signedrank test compare ABT751 pharmacokinetic parameters administered combination CAPIRI In addition unbound ABT751 pharmacokinetic parameters Wilcoxon matchedpairs signedrank test compare parameters administered bevacizumab The priori level significance set P 05 Statistical analysis performed JMPTM statistical discovery software SAS Institute Cary North Carolina Results Patient Characteristics Thirty patients advanced colorectal cancer consented 24 patients started treatment study conducted 2 US centers Four patients treated leadin phase reasons including toxicity poor compliance discovery brain metastases needing surgery noncancer diag nosis There 17 males 7 females median age 575 range 3482 Most patients colon cancer primary site 15 colon3 rectal6 colorectal treated 1 chemotherapy regimen previously n 10 receuved 2 regimens n 5 Safety Tolerability A total 106 treatment cycles administered 20 patients 5 dose levels The median number treatment cycles patient 55 range 125 Only 21 patients evaluated toxicity 4 patients came study prior initiation combina tion therapy Treatmentrelated toxicities dose level observed 10 patients summarized Table 2 The common toxicities mainly gastroin including nausea andor vomiting 91 testinal grade 34 5 diarrhea 72 5 abdomi nal pain 48 10 elevated liver function tests 39 Constitutional symptoms fa tigue 52 anorexia 19 neutropenia 59 noticed commonly The common grade cid23 toxicities included neutropenia 29 abdom inal pain 10 bowel obstruction 10 Of patients developing neutropenia 2 febrile neutropenia Dose escalation summarized Table 1 One patient dose level 2 developed grade 2 gas trointestinal toxicities including nausea vomiting diarrhea 3 days irinotecan infusion noted grade 3 hypokalemia day 8 requiring intravenous replacement On day 15 cycle 1 noted grade 3 elevation ALT resolved grade 1 day 20 She subsequently dose reduced dose level 1 treated additional 4 cycles Another patient dose level 2b developed grade 4 febrile neutropenia clear infectious source 1 week initiating CAPIRI responded intravenous antibiotics This patient subsequently taken study request Given DLTs noted dose levels 2 2b 3 DLTs 6 patients decided enrolling 3 additional patients dose level 2b safety concerns Therefore dose level 1b reduceddose CAPIRI ABT751 150 mg orally daily days 1 14 combination bevacizumab tested DLTs observed However multiple intolerable grade cid23 toxicities noted DLT occurred cycle 1 They related peripheral neuropathic effects ABT751 including bowel obstruction 1 constipation 1 abdominal pain 2 grade 1 2 neuropathy 2 Therefore protocol amended test dose CAPIRI bevacizumab reduced dose 970 The Journal Clinical Pharmacology Vol 56 No 8 2016 Table 2 Dose Levels Explored Dose Level Number Patients leadincombination phase 1 2 2b 1b 3 33 43 43 54 88 aOral daily days 114 bIntravenous day 1 cOral divided twicedaily dosing days 114 ABT751a 150 mg 150 mg 150 mg 150 mg 125 mg Irinotecanb 200 mgm2 250 mgm2 250 mgm2 200 mgm2 250 mgm2 Capecitabinec Bevacizumabb 1600 mgm2 2000 mgm2 2000 mgm2 1600 mgm2 2000 mgm2 75 mgkg 75 mgkg 75 mgkg Table 3 TreatmentRelated Side Effects During Treatment Phase Dose Level Least 10 Total Patients DL 1 n 3 DL2 n 3 DL2b n 3 DL 1b n 4 DL3 n 8 Total n 21 Toxicity G G 12 G 34 G 12 G 34 G 12 G 34 G 12 G 34 G 12 G 34 G 12 G 34 Neutropenia Fever Abdominal pain Nauseavomiting Diarrhea Bowel obstruction Constipation AnorexiaWt loss Elevated ALTAST Elevated Alk Phos Hyperbilirubinemia Hypokalemia Hypophosphatemia Hyperglycemia Proteinuria Mucositis Fatigue Neuropathy Rash Headache Pain Alopecia Anemia Handfoot syndrome 1 1 2 1 1 1 2 1 1 1 1 1 1 1 2 1 3 2 6 3 1 1 3 2 2 2 2 1 1 1 2 1 1 1 1 1 1 4 1 5 7 6 1 1 1 3 2 1 1 2 2 1 4 1 4 2 2 1 1 1 1 1 6 29 2 10 1 5 1 5 2 10 1 5 1 5 1 5 1 5 1 5 1 5 1 5 8 38 1 5 8 38 18 86 14 67 1 10 2 10 4 19 2 10 3 14 2 10 1 5 1 5 5 24 2 10 2 10 11 52 5 24 1 5 2 10 3 14 4 19 3 14 7 33 1 3 2 1 1 1 2 1 2 DL dose level G toxicity grade NCI CTC version 3 criteria Toxicities worstgrade treatmentrelated occurring cycle ABT751 125 mg orally daily days 1 14 cohort 3 No DLTs noted 3 patients plus 5 additional subjects treated dose level deemed MTD Response Evaluation Of 30 patients consented trial 24 eligible started treatment included intenttotreat efficacy evaluation One previously untreated patient isolated liver lesion complete radiographic response CR 5 cycles underwent surgical resection Two patients 8 partial responses PR 1 confirmed 1 unconfirmed In addition 10 patients 41 stable disease duration 2 25 cycles Pharmacokinetics ABT751 pharmacokinetic sampling evaluable 20 patients ABT751 administered 15 patients ABT751 administered combination CAPIRI Table 3 There appeared decrease extent AUCτ slight increase rate Cmax formation ABT 751 glucuronide ABT751 administered CAPIRI The altered glucuronidation ABT751 affect exposure active parent compound ABT 751 sulfate Because alterations ABT 751 glucuronide pharmacokinetics determined ABT751 undergoes glucuronidation UGT1A8 1A4 lesser extent UGT1A1 UGT1A7 UGT2B7 Table 4 Table 5 Rudek et al 971 Table 4 ABT751 Irinotecan Pharmacokinetic Parameters Cmax μgmL Tmax h AUCa μg cid5 hmL AUC ratio b ABT751 Pharmacokineticsc Total ABT751 Alone Combination Unbound ABT751 Alone Combination ABT751 Sulfate Alone Combination ABT751 Glucuronide Alone Combination Irinotecan Pharmacokineticsd Irinotecan SN38 SN38 glucuronidee APC 86 31 20 85 24 15 08 04 20 07 02 15 64 30 20 77 33 15 52 19 20 54 24 15 31 07 17 01 00 17 03 02 10 06 03 17 17 0550 20 20 0141 15 17 0560 20 20 0141 15 34 2064 20 31 0555 15 40 2064 20 43 1085 15 19 1438 17 29 05260 17 37 1959 10 42 1970 17 374 57 15 415 172 14 32 09 15 34 17 14 748 379 15 778 364 14 639 238 15 541 185 14 295 144 14 08 033 8 NC 79 51 16 NA NA 83 14 15 80 10 14 1637 697 15 1682 912 14 1161 366 15 964 379 14 NA 26 23 8 NC 268 354 16 Data presented mean SD n median range n Tmax AUC area concentrationtime curve Cmax maximum plasma concentration NA applicable NC calculated Tmax time Cmax SD standard deviation aFor ABT751 AUCτ reported For irinotecan AUCcid4 reported bRatio unbound ABT751 ABT751 sulfate ABT751 glucuronide ABT751 SN38 APC SN38 glucuronide irinotecan expressed percentage cCmax AUCcid4 dose normalized 150 mg dCmax AUCcid4 dose normalized 250 mgm221 eSeven patients undetectable SN38 glucuronide concentrations Of 10 detectable levels halflife percentage extrapolated AUC poor AUCcid4 calculated P 05 matched pair comparison administered combination CAPIRI Table 5 Kinetic Parameters ABT751 Glucuronide Formation UGT1A4 UGT1A8a UGT1A4 UGT1A8 Km μM 837 309 270 73 Vmax pmolmin mg P450 VmaxKm mLmin mg 599 202 1970 238 07 73 Results expressed mean SD n 3 experiments n 3 replicates concentration aDue analytical assay limits accurate kinetic parameters ABT751 glucuronide formation unable calculated UGT1A1 UGT1A7 UGT2B7 Glucuronidation ABT751 extensively bound human plasma obtained healthy volunteers mean unbound fraction value 82 06 The unbound fraction determined 84 14 patients study altered concentrationtime profile administered combination ABT 751 bound exclusively albumin unbound fraction 56 01 AAG 844 11 Seventeen patients irinotecan pharmacoki netic sampling Table 3 Irinotecan APC exposure increased SN38 exposure similar SN 38 glucuronide exposure decreased compared historical controls24 Discussion ABT751 orally available sulfonamide causes G2M cell cycle arrest subsequent apopto sis microtubule inhibition acting colchicinebinding site βtubulin ABT751 substrate multiple drug resistance MDR transporter23812 Subsequent research sug gested ABT751 acts vascular disrupting agent disruption tubulin cytoskeleton endothelial cells ultimately leading decreased blood flow tumor necrosis25 The primary objectives trial determine MTD toxicity profile ABT751 combination bevacizumab CAPIRI advanced colorectal cancer Several DLTs observed original escalation deemed related CAPIRI cohort explored reduceddose CAPIRI combination ABT751 150 mg added bevacizumab NonDLT intolerable toxicities occurred related peripheral neuropathic effects ABT751 lower dose level ABT751 explored ultimately deemed 972 The Journal Clinical Pharmacology Vol 56 No 8 2016 MTD However combination studies evaluat ing similar dosing schedule ABT751 days 1 14 21day cycle suggested higher MTDs 200 mg combination pemetrexed lung cancer26 docetaxel prostate cancer14 The reason reduced tolerability ABT751 current trial unclear In order assess interaction looked unbound ABT751 drug glucuronidated unknown time clinical trial conducted Our vitro studies confirmed Innocenti colleagues demonstrated highest affinity UGT1A8 UGT1A4 followed minor clearance UGT1A1 UGT2B731 More functional importantly polymorphisms UGT1A8 UGT1A4 SULT1A1 copy number alter pharmacokinetics ABT751 Unfortunately collect pharmacogenomic samples explore variability patient population The active metabolite irinotecan SN38 primarily eliminated gluruonidation UGT1A1 UGT1A7 UGT1A932 Because UGT isozymes responsible metabolism irinotecan ABT751 different alteration unlikely competitive isozymes likely substrate depletion29 A limitation current study rely historical control comparisons irinotecan pharma cokinetics During initial development CAPIRI noted capecitabine decreased rate formation SN38 SN38 glucuronide transient period beginning coadministration30 It ruled alterations observed ABT751 glucuronide capecitabine However alteration ABT751 pharmacokinetics CAPIRI significant explain increased toxicity At time initiation trial capecitabine evaluated replacement 5FU FOLFIRI regimen However large trials convincingly shown increased toxicity combination overlapping toxicity profiles capecitabine irinotecan3132 The randomized BICCC trial compared FOLFIRI modified IFL irinotecan plus bolus FULV CAPIRI later amendment adding bevacizumab arms In trial CAPIRI arm associated significantly higher rates severe vomiting diarrhea dehy dration discontinued33 Since results trials published CAPIRI fallen favor 5FU fluoropyrimidine choice combination therapies irinotecan Given 2 patients cid2 2 prior chemother apy regimens rest chemotherapy naive cid3 1 prior systemic chemotherapy regimen activity regimen modest 1 CR 1 confirmed PR The BICCC trial convincingly showed inferior outcomes CAPIRI compared FOLFIRI33 Also early clinical evidence antitumor activity ABT751 encouraging In conclusion MTD combination ABT751 CAPIRI bevacizumab advanced colorectal cancer ABT751 125 mg orally days 1 14 irinotecan 250 mgm2 intravenous day 1 capecitabine 2000 mgm2 orally daily 2 divided doses bevacizumab 75 mgkg IV day 1 3 weeks Although combination activity colorectal cancer previous trials showed decreased efficacy CAPIRI compared FOLFIRI increased toxicity ABT751 noted trial unclear reasons Therefore combination evaluated colorectal cancer Acknowledgments This research supported Analytical Pharmacol ogy Core Sidney Kimmel Comprehensive Cancer Center Johns Hopkins NIH P30 CA006973 Correlative studies supported National Institutes Health grant P30CA069773 Commonwealth Foundation Cancer Research We like thank Sharyn Baker scientific dis cussions Ming Zhao assistance sample analyses Susan Davidson quality assurance data References 1 Jemal A Siegel R Xu J Ward E Cancer statistics 2010 CA 201060277300 2 Gelfand VI Bershadsky AD Microtubule dynamics mecha nism regulation function Annu Rev Cell Biol 1991793 116 3 Fox E Maris JM Cohn SL et al Pharmacokinetics orally administered ABT751 children neuroblastoma solid tumors Cancer Chemother Pharmacol 201066737743 4 Segreti JA Polakowski JS Koch KA et al Tumor selective tivascular effects novel antimitotic compound ABT751 vivo rat regional hemodynamic study Cancer Chemother Pharmacol 200454273281 5 Yoshimatsu K Yamaguchi A Yoshino H Koyanagi N Kitoh K Mechanism action E7010 orally active sulfonamide titumor agent inhibition mitosis binding colchicine site tubulin Cancer Res 19975732083213 6 Ogawa M Ariyoshi Y New anticancer drugs clinical trials Japan Hematol Oncol Clin North Am 19948277287 7 Koyanagi N Nagasu T Fujita F et al In vivo tumor growth inhibition produced novel sulfonamide E7010 rodent human tumors Cancer Res 19945417021706 8 Yoshino H Ueda N Niijima J et al Novel sulfonamides potential systemically active antitumor agents J Med Chem 19923524962497 9 Hande KR Hagey A Berlin J et al The pharmacokinetics safety ABT751 novel orally bioavailable sulfonamide Rudek et al 973 antimitotic agent results phase 1 study Clin Cancer Res 20061228342840 patients solid tumors Cancer Chemother Pharmacol 200861423433 10 Jorgensen TJ Tian H Joseph IB Menon K Frost D Chemosen sitization radiosensitization human lung colon cers antimitotic agent ABT751 athymic murine xenograft models subcutaneous tumor growth Cancer Chemother Phar macol 200759725732 11 Hande KR Hagey A Berlin J Cai Y Meek K Kobayashi H Lockhart AC Medina D Sosman J Gordon GB Rothen berg ML The pharmacokinetics safety ABT751 novel orally bioavailable sulfonamide antimitotic agent sults phase 1 study Clin Cancer Res 20061292834 2840 12 Yee KW Hagey A Verstovsek S et al Phase 1 study ABT751 novel microtubule inhibitor patients refrac tory hematologic malignancies Clin Cancer Res 2005116615 6624 13 Fox E Maris JM Widemann BC et al A phase 1 study ABT 751 orally bioavailable tubulin inhibitor administered daily 7 days 21 days pediatric patients solid tumors Clin Cancer Res 20061248824887 14 Michels J Ellard SL Le L et al A phase IB study ABT 751 combination docetaxel patients advanced castrationresistant prostate cancer Ann Oncol 201021305 311 15 Saltz LB Clarke S DiazRubio E et al Bevacizumab combi nation oxaliplatinbased chemotherapy firstline therapy metastatic colorectal cancer randomized phase III study J Clin Oncol 20082620132019 16 Giantonio BJ Catalano PJ Meropol NJ et al Bevacizumab combination oxaliplatin fluorouracil leucovorin FOLFOX4 previously treated metastatic colorectal cancer results Eastern Cooperative Oncology Group Study E3200 J Clin Oncol 20072515391544 17 Therasse P Arbuck SG Eisenhauer EA et al New guidelines evaluate response treatment solid tumors European Organization Research Treatment Cancer National Cancer Institute United States National Cancer Institute Canada J Natl Cancer Inst 200092205216 18 Rudek MA Zhao M He P Messersmith WA Baker SD Vali dation implementation liquid chromatographytandem mass spectrometry assay quantitate ABT751 ABT751 glu curonide ABT751 sulfate human plasma clinical pharmacology studies J Pharm Biomed Anal 200642253 260 19 Li J Brahmer J Messersmith W Hidalgo M Baker SD Binding gefitinib inhibitor epidermal growth factor receptor tyrosine kinase plasma proteins blood cells vitro cancer patients Invest New Drugs 200624291297 20 van Erp NP Baker SD Zhao M et al Effect milk thistle Silybum marianum pharmacokinetics irinotecan Clin Cancer Res 20051178007806 21 Jimeno A Rudek MA Purcell T et al Phase I phar macokinetic study UCN01 combination irinotecan 22 Falcone A Di Paolo A Masi G et al Sequence effect irinote fluorouracil treatment pharmacokinetics toxicity chemotherapynaive metastatic colorectal cancer patients J Clin Oncol 20011934563462 23 Rudek MA Venitz J Ando Y Reed E Pluda JM Figg WD Fac tors involved pharmacokinetics COL3 matrix met alloproteinase inhibitor patients refractory metastatic cancer clinical experimental studies J Clin Pharmacol 20034311241135 24 Delord JP Pierga JY Dieras V et al A phase I clinical pharmacokinetic study capecitabine Xeloda irinotecan combination therapy XELIRI patients metastatic gas trointestinal tumours Br J Cancer 200592820826 25 Siemann DW Bibby MC Dark GG et al Differentiation definition vasculartargeted therapies Clin Cancer Res 200511416420 26 Rudin CM Mauer A Smakal M et al Phase III study pemetrexed ABT751 advanced metastatic nonsmallcell lung cancer J Clin Oncol 20112910751082 27 Innocenti F Ramırez J Obel J Xiong J Mirkov S Chiu YL Katz DA Carr RA Zhang W Das S Adjei A Moyer AM Chen PX Krivoshik A Medina D Gordon GB Ratain MJ Sahelijo L Weinshilboum RM Fleming GF Bhathena A Preclinical discovery candidate genes guide pharmacogenetics phase I development example novel anticancer agent ABT751 Pharmacogenet Genomics 2013237374381 doi 101097FPC0b013e3283623e81 28 Rosner GL Panetta JC Innocenti F Ratain MJ Pharmaco genetic pathway analysis irinotecan Clin Pharmacol Ther 2008843393402 doi 101038clpt200863 29 Gagne JF Montminy V Belanger P Journault K Gaucher G Guillemette C Common human UGT1A polymorphisms altered metabolism irinotecan active metabolite 7ethyl 10hydroxycamptothecin SN38 Mol Pharmacol 200262608 617 30 Czejka M Schueller J Hauer K Ostermann E Pharmacokinet ics metabolism irinotecan combined capecitabine patients advanced colorectal cancer Anticancer Res 200525429852990 31 Borner MM Bernhard J Dietrich D et al A randomized phase II trial capecitabine different schedules irinotecan firstline treatment metastatic colorectal cancer efficacy qualityoflife toxicity Ann Oncol 200516282288 32 Patt YZ Lee FC Liebmann JE et al Capecitabine plus 3 weekly irinotecan XELIRI regimen firstline chemotherapy metastatic colorectal cancer phase II trial results Am J Clin Oncol 200730350357 33 Fuchs CS Marshall J Mitchell E et al Randomized controlled trial irinotecan plus infusional bolus oral fluoropyrim idines firstline treatment metastatic colorectal cancer results BICCC Study J Clin Oncol 2007254779 4786